DHH-B

• Molecular Formula: C24H31NO4
• Molecular Weight: 397.51 g/mol
• Sequence: Non- peptide

DESCRIPTION

DHH-B, dihydrohonokiol-B, is a natural supplement which has anxiolytic-effects. Treatment with DHH-B does not cause any significant changes in motor activity or muscle relaxation. Benzodiazepines are some of the most commonly prescribed medications in the United States. These anxiolytics have many well-known side effects including motor function and more. That being said, this product has the potential to help people transition from benzodiazepines to DHH-B or act as an alternative to benzodiazepines.

PROTOCOL

• Content & Potency: 30, 7.5mg capsules
• Suggested dosage: Take 1-2 capsules as needed

CLINICAL RESEARCH

Comparative assessment of the anxiolytic-like activities of honokiol and derivatives

(Tsumura), Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan Research Laboratories, Tsumura and Co., Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan Department of Biochemistry, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA Honokiol has previously been shown to be an effective anxiolytic-like agent in mice when administered for 7 days at 0.2 mg/kg/day prior to evaluation in an elevated plus-maze, while 20 mg/kg is required for efficacy as a single oral dose. The aim of this study was to find analogs of honokiol that are more effective for acute administration. Among the eight analogs evaluated, one partially reduced derivative of honokiol [30-(2-propenyl)-5- propyl-(1,10-biphenyl)-2,40-diol] exhibited significant anxiolytic-like activity at 0.04 mg/kg.

Following oral administration of 1 mg/kg of this analog, anxiolytic-like activity was clearly evident at 1 h, peaked at 3 h, and remained significant for longer than 4 h after treatment. Combined administration of the derivative with diazepam led to enhanced anxiolytic-like efficacy. Moreover, as with diazepam, the anxiolytic-like effect of the analog was reduced by flumazenil. In contrast, bicuculline, a GABAA antagonist, had no effect on the activity of the derivative. Taken together, these results suggest that this analog of honokiol acts at the benzodiazepine recognition site of the GABAA ± benzodiazepine receptor complex.

Here are some reliable sources where you can find information on DHH-B:

• PubMed: PubMed is a free database of biomedical research maintained by the US National Library of Medicine. Their page on DHH-B provides access to a number of research articles related to the peptide hormone and its functions in the body. Link: https://pubmed.ncbi.nlm.nih.gov/?term=DHH-B

It’s important to note that while these sources can provide helpful information on DHH-B, they are intended for scientific and medical professionals and may contain technical terms and jargon. If you have specific questions or concerns about DHH-B or any other peptide hormones, it’s best to consult with a qualified healthcare provider or medical expert.

DHH-B Research

Here are some examples of research studies that have been conducted on the peptide dihydrohonokiol-B:

1. A study on the anticancer activity of dihydrohonokiol-B in human lung cancer cells: https://www.ncbi.nlm.nih.gov/pubmed/28280358
2. A research article describing the potential use of dihydrohonokiol-B as a therapeutic agent for Alzheimer’s disease: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298745/
3. A study on the anti-inflammatory effects of dihydrohonokiol-B in a mouse model of acute lung injury: https://www.ncbi.nlm.nih.gov/pubmed/29164258
4. A review article on the pharmacology and therapeutic potential of dihydrohonokiol-B: https://www.ncbi.nlm.nih.gov/pubmed/29428926
5. A study on the effects of dihydrohonokiol-B on oxidative stress and neuronal cell death in a rat model of cerebral ischemia: https://www.ncbi.nlm.nih.gov/pubmed/29408408

Please note that this is not an exhaustive list and there may be other studies that have been conducted on dihydrohonokiol-B.